Canopy Growth launches 7Acres brand in Australia

Executive Summary

• Canopy Growth Corp. has launched its Canadian-grown 7Acres brand in Australia, expanding its global medical cannabis portfolio.
• The initial launch features two high-THC sativa strains, Ultra Jack and Jack Frost, available in 10-gram flower formats.
• This move complements Canopy's existing Australian presence, which includes Tweed flower products and Spectrum Therapeutics oils, reinforcing the company's focus on scalable international medical platforms.

Key Details

• Brand Launch: Introduction of the 7Acres brand into the Australian market.
• Product Specifications:
  • Strain 1: Ultra Jack (a cross of Ultra Sour and Jack Haze), noted as a top-performing strain in Canadian medical and adult-use markets.
  • Strain 2: Jack Frost (a cross of White Widow and Cold Creek Kush), added to provide genetic depth.
  • Format: Both strains are initially available in 10-gram flower formats.
• Strategic Context: The launch leverages recent improvements to Canopy's global supply chain to ensure consistent quality and reliable access for patients and prescribers in Australia.
• Existing Portfolio Integration: The new 7Acres products complement existing Australian offerings, specifically Tweed flower products and Spectrum Therapeutics oils (available in red, yellow, white, and blue formulations).
• Management Commentary:
  • Andrew Bevan, Senior Vice-President, Global Medical, emphasized the goal of providing a diverse range of high-quality flower options.
  • Luc Mongeau, CEO, highlighted global medical as one of the company's largest commercial opportunities and cited reliable international supply as a key strength.

Notable Quotes

• "Adding 7Acres to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options," said Andrew Bevan, senior vice-president, global medical.
• "Global medical is one of Canopy Growth's largest commercial opportunities," said Luc Mongeau, chief executive officer. "Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform."